{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:46:01Z","timestamp":1795067161545,"version":"4.10.2"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-007958"],"award-info":[{"award-number":["INV-007958"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.vaccine.2025.128019","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T19:28:53Z","timestamp":1764444533000},"page":"128019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants"],"prefix":"10.1016","volume":"70","author":[{"given":"Tushar","family":"Tewari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Armah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A.","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C.","family":"Chisenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Kukula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuzwayo C.","family":"Jere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelo","family":"Simuyandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Damanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson","family":"Mwinjiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayi","family":"Kazimbaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Atuguba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Chilengi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Csedrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Fix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Cryz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2025.128019_bb0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(24)00691-1","article-title":"Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990\u20132021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021","volume":"25","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128019_bb0010","author":"Global immunization coverage"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128019_bb0015","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/S2214-109X(19)30207-4","article-title":"Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008-16: findings from the global rotavirus surveillance network","volume":"7","author":"Aliabadi","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.128019_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Rotavirus efficacy and safety trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.128019_bb0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/01.inf.0000141722.10130.50","article-title":"Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants","volume":"23","author":"Vesikari","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128019_bb0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9741","key":"10.1016\/j.vaccine.2025.128019_bb0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"9935","key":"10.1016\/j.vaccine.2025.128019_bb0040","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0140-6736(13)62630-6","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial","volume":"383","author":"Bhandari","year":"2014","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.vaccine.2025.128019_bb0045","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/j.vaccine.2017.09.014","article-title":"A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants","volume":"35","author":"Kulkarni","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.128019_bb0050","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.vaccine.2011.10.108","article-title":"Rotavirus vaccines for children in developing countries: understanding the science, maximizing the impact, and sustaining the effort","volume":"30","author":"Neuzil","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.128019_bb0055","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1086\/605035","article-title":"Oral rotavirus vaccines: how well will they work where they are needed most?","volume":"200","author":"Patel","year":"2009","journal-title":"J Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2025.128019_bb0060","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.vaccine.2015.05.024","article-title":"Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults","volume":"33","author":"Fix","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128019_bb0065","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(17)30242-6","article-title":"Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial","volume":"17","author":"Groome","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2025.128019_bb0070","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1473-3099(20)30001-3","article-title":"Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Groome","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.128019_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/00365549009027046","article-title":"Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes","volume":"22","author":"Ruuska","year":"1990","journal-title":"Scand J Infect Dis"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2025.128019_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0166-0934(91)90013-P","article-title":"Development of an improved method for measuring neutralizing antibody to rotavirus","volume":"33","author":"Knowlton","year":"1991","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2025.128019_bb0095","series-title":"Group sequential methods with applications to clinical trials","author":"Jennison","year":"1999"},{"key":"10.1016\/j.vaccine.2025.128019_bb0100","author":"Anderson"},{"key":"10.1016\/j.vaccine.2025.128019_bb0105","series-title":"_R: A language and environment for statistical Computing_","author":"R Core Team","year":"2024"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.128019_bb0110","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1016\/j.vaccine.2011.08.080","article-title":"Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Madhi","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128019_bb0115","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.vaccine.2022.02.003","article-title":"The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality","volume":"40","author":"Henschke","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128019_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106156","article-title":"Truncated rotavirus VP4 proteins induce stronger protective immunity compared to P2 - VP8 in animal models","volume":"238","author":"Chen","year":"2025","journal-title":"Antivir Res"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128019_bb0125","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1080\/21645515.2019.1619400","article-title":"Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development","volume":"15","author":"Velasquez","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2025.128019_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/jpids\/piab120","article-title":"Plasma VP8\u2217-binding antibodies in rotavirus infection and Oral vaccination in young Bangladeshi children","volume":"11","author":"Lee","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"12","key":"10.1016\/j.vaccine.2025.128019_bb0135","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.4161\/hv.34361","article-title":"Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges","volume":"10","author":"Angel","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2025.128019_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008732","article-title":"Intracellular neutralisation of rotavirus by VP6-specific IgG","volume":"16","author":"Caddy","year":"2020","journal-title":"PLoS Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25013179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25013179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:05:03Z","timestamp":1766120703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25013179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0264410X25013179"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128019"}}